# Certara, Inc. (CERT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $845M  
**Price:** $5.27 (+1.74%)

> Certara, Inc. is a global leader in biosimulation science, technology, and consulting services that transform drug development through model-informed drug development (MIDD). The company provides proprietary biosimulation platforms, software products, and expert consulting services designed to help biopharmaceutical and biotech organizations design better clinical trials, optimize drug development decisions, and accelerate regulatory approval processes. Certara's software solutions include mechanistic and empirical biosimulation models, pharmacometric analysis tools, and the Pinnacle 21 family of clinical data management products. The company also offers specialized services spanning drug development strategy, clinical pharmacology, regulatory science, and submission management across major health agencies including the FDA, EMA, and China's NMPA. In 2024, Certara acquired Chemaxon to strengthen its drug discovery capabilities through chemical property prediction and in-silico development tools. The platform integrates artificial intelligence capabilities within validated scientific frameworks to enhance modeling productivity and data connectivity. Certara's solutions serve more than 2,600 life sciences organizations globally, including 38 of the top 40 biopharmaceutical companies by R&D spend, with customers receiving the majority of novel drug approvals from the FDA. Founded in 2008 and headquartered in Radnor, Pennsylvania, Certara operates across the Americas, Europe, Middle East, Africa, and Asia Pacific.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $419M | — | $21M | -$2M | — |
| 2024 | $385M | — | -$2M | -$12M | — |
| 2023 | $354M | $213M | -$41M | -$55M | — |
| 2022 | $336M | $203M | $33M | $15M | — |
| 2021 | $286M | $174M | $14M | -$13M | — |
| 2020 | $244M | $143M | -$24M | -$49M | — |
| 2019 | $209M | $129M | $20M | -$9M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.56B | $494M | $1.06B | $189M | $293M |
| 2024 | $1.58B | $516M | $1.06B | $179M | $295M |
| 2023 | $1.56B | $516M | $1.05B | $235M | $291M |
| 2022 | $1.57B | $493M | $1.08B | $237M | $293M |
| 2021 | $1.51B | $470M | $1.04B | $186M | $295M |
| 2020 | $1.27B | $447M | $822M | $271M | $299M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $96M | $2M | $95M |
| 2024 | $80M | $2M | $79M |
| 2023 | $83M | $2M | $81M |
| 2022 | $93M | $1M | $91M |
| 2021 | $60M | $1M | $59M |
| 2020 | $45M | $863,000 | $44M |
| 2019 | $38M | $2M | $36M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CERT)